Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: InMed Pharmaceuticals Inc. INM

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has closed on a private placement agreement with two healthcare-focused institutional investors. The agreement consisted of the issue and sale of 691,245 of INM common … Continue reading

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment